Replies to post #129 on Elan Corp PLC (ELN)

[io_io]

Dew, it is erroneous to refer to aab-001 as a candidate for Glaucoma.

In fact aab-001 is just the designation of the anti-body in the Wyeth-Elan agreement addressing Alzheimer's.

Instead the correct term is Bapineuzumab, as the anti-body is named.

I will post a correction with a superior link in order to supercede your error.